Sentiment-Signal
Score-Verlauf (90 Tage)
Stammdaten
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Unternehmen & Branche
| Name | Intellia Therapeutics, Inc. |
|---|---|
| Ticker | NTLA |
| CIK | 0001652130 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2835 · In Vitro & In Vivo Diagnostic Substances |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 1,65 Mrd. USD |
| Beta | 1,99 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 67,671,000 | -412,694,000 | -3.81 | 842,127,000 | 671,394,000 |
| 2025-09-30 | 10-Q | 13,782,000 | -101,324,000 | -0.92 | 925,275,000 | 748,422,000 |
| 2025-06-30 | 10-Q | 14,245,000 | -101,255,000 | -0.98 | 898,894,000 | 715,255,000 |
| 2025-03-31 | 10-Q | 16,627,000 | -114,329,000 | -1.10 | 986,163,000 | 779,919,000 |
| 2024-12-31 | 10-K | 57,877,000 | -519,021,000 | -5.25 | 1,191,015,000 | 871,956,000 |
| 2024-09-30 | 10-Q | 9,111,000 | -135,712,000 | -1.34 | 1,173,351,000 | 962,615,000 |
| 2024-06-30 | 10-Q | 6,957,000 | -146,975,000 | -1.52 | 1,191,536,000 | 971,062,000 |
| 2024-03-31 | 10-Q | 28,935,000 | -107,436,000 | -1.12 | 1,259,589,000 | 1,036,137,000 |
| 2023-12-31 | 10-K | 36,275,000 | -481,192,000 | -5.42 | 1,300,977,000 | 1,050,169,000 |
| 2023-09-30 | 10-Q | 11,992,000 | -122,224,000 | -1.38 | 1,243,349,000 | 1,037,414,000 |
| 2023-06-30 | 10-Q | 13,594,000 | -123,681,000 | -1.40 | 1,323,240,000 | 1,104,888,000 |
| 2023-03-31 | 10-Q | 12,606,000 | -103,126,000 | -1.17 | 1,417,889,000 | 1,190,843,000 |
| 2022-12-31 | 10-K | 52,121,000 | -474,186,000 | -6.16 | 1,520,114,000 | 1,235,584,000 |
| 2022-09-30 | 10-Q | 13,266,000 | -113,229,000 | -1.49 | 1,084,458,000 | 824,951,000 |
| 2022-06-30 | 10-Q | 14,030,000 | -100,678,000 | -1.33 | 1,110,424,000 | 880,547,000 |
| 2022-03-31 | 10-Q | 11,252,000 | -146,872,000 | -1.96 | 1,202,788,000 | 953,754,000 |
| 2021-12-31 | 10-K | 33,053,000 | -267,892,000 | -3.78 | 1,294,464,000 | 1,040,244,000 |
| 2021-09-30 | 10-Q | 7,204,000 | -71,644,000 | -0.97 | 1,334,961,000 | 1,107,098,000 |
| 2021-06-30 | 10-Q | 6,550,000 | -68,806,000 | -1.01 | 672,243,000 | 494,813,000 |
| 2021-03-31 | 10-Q | 6,445,000 | -46,205,000 | 716,891,000 | 545,873,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-01-05 | Dulac Edward J III | Officer, EVP, Chief Financial Officer | Open Market Sale | -6,379 | 9.21 | -58,750.59 | -15,7% | |
| 2026-01-05 | LEONARD JOHN M | Director, Officer, President and CEO | Open Market Sale | -34,146 | 9.21 | -314,484.66 | -83,9% | |
| 2026-01-05 | Cohen Fred E | Director | Open Market Purchase | 150,000 | 9.35 | 1,402,500.00 | +374,1% | |
| 2025-12-11 | LEONARD JOHN M | Director, Officer, President and CEO | Open Market Sale | -32,832 | 9.47 | -310,919.04 | -82,9% | |
| 2025-12-11 | LEONARD JOHN M | Director, Officer, President and CEO | Open Market Sale | -5,355 | 9.59 | -51,354.45 | -13,7% | |
| 2025-12-11 | LEONARD JOHN M | Director, Officer, President and CEO | Open Market Sale | -49,959 | 9.49 | -474,110.91 | -126,5% | |
| 2025-08-20 | CHASE WILLIAM J | Director | Open Market Purchase | 100,000 | 10.03 | 1,003,000.00 | +267,6% | |
| 2025-07-23 | Dulac Edward J III | Officer, EVP, Chief Financial Officer | Open Market Sale | -7,462 | 14.02 | -104,617.24 | -27,9% | |
| 2025-07-01 | GOODMAN JESSE | Director | Open Market Sale | -1,547 | 9.23 | -14,278.81 | -3,8% | |
| 2025-06-30 | GOODMAN JESSE | Director | Open Market Sale | -1,547 | 9.56 | -14,789.32 | -3,9% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.